{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:23:40Z","timestamp":1787495020064,"version":"build-2736575974"},"reference-count":40,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1185\/03007991003694340","type":"journal-article","created":{"date-parts":[[2010,3,3]],"date-time":"2010-03-03T09:02:41Z","timestamp":1267606961000},"page":"1037-1045","source":"Crossref","is-referenced-by-count":48,"title":["Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer"],"prefix":"10.1185","volume":"26","author":[{"given":"Debby","family":"Vissers","sequence":"first","affiliation":[{"name":"Mapi Values, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiro","family":"Stam","sequence":"additional","affiliation":[{"name":"Mapi Values, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Nolte","sequence":"additional","affiliation":[{"name":"Schmerz- und Palliativzentrum, Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Lenre","sequence":"additional","affiliation":[{"name":"Nycomed, Taastrup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Jansen","sequence":"additional","affiliation":[{"name":"Mapi Values, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2010,3,3]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2354.2008.01009.x"},{"key":"e_1_3_3_3_1","first-page":"354","article-title":"Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2 management","volume":"6","author":"Bennett D","year":"2005","unstructured":"Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2 management. Pharm Ther 2005;6:354-61","journal-title":"Pharm Ther"},{"key":"e_1_3_3_4_1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0304-3959(90)90004-W","article-title":"Breakthrough pain: definition, prevalence and characteristics","volume":"3","author":"Portenoy RK","year":"1990","unstructured":"Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;3:273-81","journal-title":"Pain"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1191\/0269216304pm890oa"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(99)00006-8"},{"key":"e_1_3_3_7_1","first-page":"CD004311","article-title":"Opioids for the management of breakthrough episodic pain in cancer patients","volume":"1","author":"Zeppetella G","year":"2006","unstructured":"Zeppetella G, Ribeiro MDC. Opioids for the management of breakthrough episodic pain in cancer patients. Cochrane database of systematic reviews (Online) 2006;1:CD004311","journal-title":"Cochrane database of systematic reviews (Online)"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1054\/jpai.2002.27136"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10249"},{"key":"e_1_3_3_10_1","unstructured":"Summary of Product Characteristics Actiq. Cephalon UK Limited Hertfordshire. Available at: http:\/\/emc.medicines.org.uk\/medicine\/11145\/SPC\/Actiq\/ [Last accessed 8 December 2009]"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1368-8375(97)00076-6"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<984::AID-CNCR6>3.0.CO;2-0"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0444-8"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-6576.2002.460702.x"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.8.611"},{"key":"e_1_3_3_16_1","first-page":"327","article-title":"Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain","volume":"7","author":"Slatkin N","year":"2007","unstructured":"Slatkin N, Xie F, Messina J, et al. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007;7:327-34","journal-title":"J Support Oncol"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ajp.0000210932.27945.4a"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.05.022"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(00)00427-9"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7521.897"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1875"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00347.x"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(00)00339-0"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(03)00162-3"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462301104095"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802633160"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-12-199906150-00008"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200727090-00002"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(03)00318-X"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02264.x"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603811"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2006.0151"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666180-00013"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(02)00522-5"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1191\/026921601678320304"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3238"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(98)00179-1"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903336135"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(02)00597-3"},{"key":"e_1_3_3_40_1","unstructured":"Summary of Product Characteristics Effentora. Cephalon UK Limited Hertfordshire. Available at: http:\/\/emc.medicines.org.uk\/printfriendlydocument.aspx?documentid=21401&companyid=2290 [Last accessed 2 February 2010]"},{"key":"e_1_3_3_41_1","unstructured":"Summary of Product Characteristics Instanyl. Nycomed UK Ltd Buckinghamshire. Available at: http:\/\/emc.medicines.org.uk\/printfriendlydocument.aspx?documentid=22242&companyid=1023 [Last accessed 2 February 2010]"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/03007991003694340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T06:10:16Z","timestamp":1733811016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/03007991003694340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,3]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1185\/03007991003694340"],"URL":"https:\/\/doi.org\/10.1185\/03007991003694340","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,3]]}}}